SCHEMBL21593290

SCHEMBL21593290

O=C(NC1CC1)c1c(OC(F)F)cc(Br)cc1OC(F)F

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIK1 P57059 14/20 0.42
SIK2 Q9H0K1 14/20 0.42
SIK3 Q9Y2K2 14/20 0.42
BMPR1B O00238 1/20 0.42
GAK O14976 1/20 0.42
RIPK2 O43353 1/20 0.42
ABL1 P00519 1/20 0.42
LCK P06239 1/20 0.42
FYN P06241 1/20 0.42
CSF1R P07333 1/20 0.42
YES1 P07947 1/20 0.42
LYN P07948 1/20 0.42
HCK P08631 1/20 0.42
KIT P10721 1/20 0.42
ACVR2A P27037 1/20 0.42
ACVRL1 P37023 1/20 0.42
ABL2 P42684 1/20 0.42
BLK P51451 1/20 0.42
LIMK1 P53667 1/20 0.42
ACVR1 Q04771 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29677144 0.93 SIK1 (0.49) SIK1SIK2SIK3BMPR1BGAK
SCHEMBL21593286 0.93 SIK1 (0.49) SIK1SIK2SIK3BMPR1BGAK
SCHEMBL21593376 0.92 POLB (0.41) SIK1SIK2SIK3BMPR1BGAK
SCHEMBL21591144 0.92 SIK1 (0.38) SIK1SIK2SIK3BMPR1BGAK
SCHEMBL30130895 0.92 POLB (0.41) SIK1SIK2SIK3BMPR1BGAK
SCHEMBL23193571 0.90 SIK1 (0.38) SIK1SIK2SIK3BMPR1BGAK
SCHEMBL23162283 0.90 SIK1 (0.43) SIK1SIK2SIK3BMPR1BGAK
SCHEMBL32691612 0.89 SIK1 (0.44) SIK1SIK2SIK3BMPR1BGAK
SCHEMBL21593377 0.88 SIK1 (0.38) SIK1SIK2SIK3BMPR1BGAK
SCHEMBL30130979 0.88 SIK1 (0.38) SIK1SIK2SIK3BMPR1BGAK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4724431-A1 BENZOFURAN DERIVATIVES AS SIK INHIBITORS AND USE THEREOF Beone Medicines I GmbH (CH) 2026-04-15 EP disclosed
US-20260085053-A1 BENZOFURAN DERIVATIVES AS SIK INHIBITORS AND THE USE THEREOF BEONE MEDICINES I GMBH (CH) 2026-03-26 US disclosed
EP-3806853-B1 COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES ONCO3R THERAPEUTICS BV (BE) 2026-03-18 EP disclosed
US-12264156-B2 Compounds and pharmaceutical compositions thereof for the treatment of diseases GALAPAGOS NV (BE) 2025-04-01 US disclosed
US-20220402911-A1 NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES GALAPAGOS NV (BE) 2022-12-22 US disclosed
US-20220402911-A1 NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES GALAPAGOS NV (BE) 2022-12-22 US disclosed
WO-2019238424-A1 NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES GALAPAGOS NV (BE) 2019-12-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260085053-A1 BENZOFURAN DERIVATIVES AS SIK INHIBITORS AND THE USE THEREOF SIK1, CHUK, SIK2 SIK1 1/4885SIK2 3/4885SIK3 5/4885
US-20220402911-A1 NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES IL1A, TNF, IL6 SIK1 3905/4885SIK2 4381/4885SIK3 3390/4885
US-12264156-B2 Compounds and pharmaceutical compositions thereof for the treatment of diseases TNF, IL1A, COL1A1 SIK1 3832/4885SIK2 4373/4885SIK3 3341/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.